Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring

被引：0
|
作者：
Gonczi, L. [1 ]
Ilias, A. [1 ]
Szanto, K. [2 ]
Kurti, Z. [1 ]
Golovics, P. A. [3 ]
Farkas, K. [2 ]
Schafer, E. [3 ]
Szepes, Z. [2 ]
Szalay, B. [4 ]
Vincze, A. [5 ]
Szamosi, T. [3 ]
Molnar, T. [2 ]
Lakatos, P. [6 ]
机构：
[1] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[2] Univ Szeged, Dept Med 1, Szeged, Hungary
[3] Mil Hosp, State Hlth Ctr, Dept Gastroenterol, Budapest, Hungary
[4] Semmelweis Univ, Dept Lab Med, Budapest, Hungary
[5] Univ Pecs, Dept Med 1, Pecs, Hungary
[6] McGill Univ, Div Gastroenterol, Hlth Ctr, Montreal, PQ, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.533
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P409
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [31] A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
    Glintborg, Bente
    Sorensen, Inge Juul
    Loft, Anne Gitte
    Lindegaard, Hanne
    Linauskas, Asta
    Hendricks, Oliver
    Hansen, Inger Marie Jensen
    Jensen, Dorte Vendelbo
    Manilo, Natalia
    Espesen, Jakob
    Klarlund, Mette
    Grydehoj, Jolanta
    Dieperink, Sabine Sparre
    Kristensen, Salome
    Olsen, Jimmi Sloth
    Nordin, Henrik
    Chrysidis, Stavros
    Pedersen, Dorte Dalsgaard
    Sorensen, Michael Veedfald
    Andersen, Lis Smedegaard
    Gron, Kathrine Lederballe
    Krogh, Niels Steen
    Pedersen, Lars
    Hetland, Merete Lund
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1426 - 1431
  • [32] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [33] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [34] Clinical Outcomes of Therapeutic Drug Monitoring in Inflammatory Bowel Disease
    Reznicek, Emily
    Moafa, Ghady
    Barnette, Brooke
    Montane, Bryce
    Ghouri, Yezaz
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S772 - S772
  • [35] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Srinivasan, Ashish
    Haifer, Craig
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 215 (09) : 435 - 435
  • [36] Efficacy of Infliximab Biosimilar for Induction and Maintenance Therapy in Inflammatory Bowel Disease After Switch From Drug Originator: A Meta-Analysis
    Kashani, Amir
    Syal, Gaurav
    Bonthala, Nirupama
    McGovern, Dermot P. B.
    David, Shih
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S390 - S390
  • [37] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Lim, David
    Bandiera, Rhiannon
    Handsley, Elizabeth
    MEDICAL JOURNAL OF AUSTRALIA, 2021,
  • [38] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Martinez-Feito, Ana
    Bravo-Gallego, Luz Yadira
    Hernandez-Breijo, Borja
    Diez, Jesus
    Garcia-Ramirez, Laura
    Jaquotot, Marta
    Plasencia-Rodriguez, Chamaida
    Nozal, Pilar
    Mezcua, Araceli
    Martin- Arranz, Maria Dolores
    Pascual-Salcedo, Dora
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [39] Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients
    Fischer, S.
    Klenske, E.
    Schmitt, H.
    Vitali, F.
    Hirschmann, S.
    Koch, F.
    Ramming, A.
    Zundler, S.
    Nagore, D.
    Uter, W.
    Neurath, M. F.
    Atreya, R.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S416 - S416
  • [40] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Ana Martínez-Feito
    Luz Yadira Bravo-Gallego
    Borja Hernández-Breijo
    Jesús Diez
    Laura García-Ramirez
    Marta Jaquotot
    Chamaida Plasencia-Rodríguez
    Pilar Nozal
    Araceli Mezcua
    María Dolores Martín- Arranz
    Dora Pascual-Salcedo
    Scientific Reports, 10
12345